微电生理: 2025年半年度业绩预告的自愿性披露公告

Group 1 - The company expects to achieve operating revenue of between 215 million to 230 million yuan in the first half of 2025, representing an increase of 16.63 million to 31.63 million yuan compared to the same period last year, which is a year-on-year increase of 8.39% to 15.95% [1] - The net profit attributable to the parent company is expected to increase by 12.99 million to 17.99 million yuan, reflecting a year-on-year increase of 76.34% to 105.73% [1] - The company reported a total profit of 17.03 million yuan and a net profit attributable to the parent company of 17.01 million yuan for the same period last year [1] Group 2 - The company focuses on breakthroughs in the cardiac electrophysiology field, leveraging a global strategy and a product matrix based on four major technological paths: "ice, fire, electricity, and magnetism" [1] - The successful launch and promotion of products such as the TrueForce® pressure monitoring radiofrequency ablation catheter and disposable star-shaped magnetic positioning catheter in overseas markets have significantly enhanced the company's competitive advantage [1] - The overall sales volume in the first half of the year has shown steady growth, leading to a significant increase in net profit [1]